Latest BioTime Inc. Stories
First-of-its-kind asthma study developed using ResearchKit framework New York, NY (PRWEB) March 09, 2015 The Icahn School of Medicine at Mount Sinai
MENLO PARK, Calif., Sept. 4, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc.
BioTime, Inc. (OTCBB:BTIM) Chief Executive Officer Michael West, Ph.D.
BioTime, Inc. (OTCBB:BTIM) Chief Executive Officer Michael West, Ph.D. will deliver a presentation this morning at the GTCbio Advances in Stem Cell Discoveries meeting in San Francisco. Dr.
BioTime, Inc. (OTCBB:BTIM) and the International Longevity Center-USA today announced a collaboration aimed at research, education and advocacy for regenerative medicine and its application in aging. Founded by President and CEO, Robert N. Butler, M.D.
BioTime, Inc. (OTCBB:BTIM) announced that it will host a conference call on which its Chief Executive Officer, Dr. Michael D. West, will discuss the opportunities presented by the recent additions to the company's stem cell technology portfolio.
BioTime, Inc. (OTCBB:BTIM) announced today that Robert N. Butler, M.D., has been elected to BioTime's Board of Directors. Dr.
BioTime, Inc., (OTCBB:BTIM) and its wholly-owned subsidiary Embryome Sciences, Inc.
International Stem Cell Corporation (OTCBB:ISCO), through its wholly owned subsidiary Lifeline Cell Technology (Lifeline), has signed a manufacturing and distribution agreement with BioTime, Inc., (OTCBB:BTIM) (Alameda, CA) and BioTime's wholly owned subsidiary Embryome Sciences, Inc., to jointly produce and distribute hundreds of new standardized human and animal stem cell lines, along with corresponding data and reagents.
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).